Background

Chronic pain sensitivity correlates with epigenetic age acceleration in some cohorts, yet replication fails across pain subtypes [1][2][3]. The inconsistency may stem from overlooking gut‑derived metabolites that simultaneously influence nociceptive signaling and cellular aging.

Hypothesis

We propose that circulating indole-3-propionic acid (IPA), a tryptophan metabolite produced by specific gut bacteria, sets a tonic threshold for heat pain perception by regulating microglial mitochondrial reactive oxygen species (ROS) production. Elevated IPA enhances microglial antioxidant capacity, lowering ROS‑mediated sensitization of nociceptive circuits and thereby raising pain tolerance. Simultaneously, IPA preserves mitochondrial DNA methylation patterns in peripheral blood mononuclear cells, slowing epigenetic age acceleration. In individuals with low‑IPA microbiomes, microglial ROS rise, pain thresholds drop, and epigenetic clocks advance faster.

Mechanistic Rationale

• IPA crosses the blood‑brain barrier and binds the pregnane X receptor (PXR) in microglia, upregulating Nrf2‑driven antioxidant genes (e.g., HO‑1, SOD2).
• Reduced mitochondrial ROS diminishes NLRP3 inflammasome activation, limiting IL‑1β release that sensitizes TRPV1 channels on peripheral afferents.
• In peripheral immune cells, IPA‑mediated PXR activation sustains NAD+ levels, supporting SIRT1‑dependent deacetylation of DNMT1, which preserves site‑specific methylation at CpGs implicated in the Horvath clock.

Testable Predictions

1. Human study – Participants stratified by fecal IPA concentration (high vs low) will show a graded difference in heat pain threshold (HPT) after controlling for age, sex, and BMI. High‑IPA group will exhibit higher HPT and lower epigenetic age acceleration (ΔAge) measured by the Hannum clock.
2. Intervention – Oral IPA supplementation (500 mg/day for 8 weeks) in low‑IPA volunteers will increase HPT by ≥15 % and reduce ΔAge by ≥1.2 years relative to placebo.
3. Mechanistic blockade – Co‑administration of a PXR antagonist (e.g., ketoconazole) will abolish IPA’s effects on both HPT and ΔAge, confirming receptor dependence.
4. Animal validation – Germ‑free mice colonized with IPA‑producing Clostridium sporogenes will display higher tail‑flick latency and lower hippocampal microglial ROS (measured by MitoSOX) compared with colonized controls; epigenetic age estimated from blood‑derived methylation will be younger.

Falsifiability

If high fecal IPA fails to predict higher pain tolerance or if IPA supplementation does not shift HPT or epigenetic age, the hypothesis is refuted. Likewise, if PXR blockade does not attenuate IPA’s effects, the proposed microglial mitochondrial pathway is unsupported.

Implications

Linking a gut microbial metabolite to both subjective pain experience and molecular aging offers a unified biomarker that could be assessed with a simple stool metabolite assay and a brief pain sensitivity test, potentially outperforming current epigenetic clocks in predictive specificity for age‑related decline.